Dr. Zung will be another asset to our Board, joining our experts from [industry and academia] to lead our strategy and ensure that we deliver on our vision and mission in the years to come.
Austin, Texas (PRWEB) February 04, 2015
The Clinical Data Interchange Standards Consortium (CDISC) began 2015 with a clear focus on the patient and clinician communities, made apparent through the continued development of 2015 Therapeutic Area (TA) Standards development projects, its role in the Coalition for Accelerating Standards and Therapies (CFAST), and the recent addition of Dr. Jonathan Zung to the CDISC Board of Directors.
Dr. Zung is the VP of Global Clinical Sciences & Operations at UCB, Chair of the TransCelerate BioPharma, Inc. (“TransCelerate”) Operations Committee, and an ex-officio member of the TransCelerate Board of Directors. Prior to his current position, Dr. Zung held numerous roles at Bristol-Myers Squibb and Pfizer; he has extensive experience as a change agent for enhancing performance and streamlining processes, particularly in the biopharmaceutical industry. “Dr. Zung brings to the CDISC Board of Directors over 20 years of expertise from large and mid-size pharmaceutical companies, as well as key leadership in organizations like TransCelerate,” stated Paula Brown Stafford, Past-Chair of the CDISC Board of Directors. “Dr. Zung will be another asset to our Board, joining our experts from clinical research organizations, academia, biopharmaceutical companies, technology service providers and healthcare organizations to lead our strategy and ensure that we deliver on our vision and mission in the years to come.” CDISC would also like to express sincere gratitude for the other 14 Directors of the CDISC Board, who are continuing to serve their terms through 2015.
Dr. Zung brings to CDISC direct involvement in TransCelerate and, thus, support for CDISC TA Standards development and the CDISC vision to inform patient care and safety through higher quality medical research. “The continued advancement and acceleration of CDISC TA standards would not be possible without a large number of supporters: our CFAST Partner, the Critical Path Institute (C-Path); other CFAST collaborators including TransCelerate, FDA, IMI and NCI; and, of course, our members, volunteers, patient advocacy groups, government agencies, academia, and many others around the world,” emphasized Dr. Rebecca Kush, CDISC President and CEO.
During 2015, CDISC has planned the launch of numerous new TA standards development projects and the use of our Shared Health and Research Electronic Library (SHARE) to improve access to these standards and speed their development. Projects include global health concerns such as malaria, Ebola virus disease, Tuberculosis and nutrition. “CDISC released a standard for Hepatitis C that is currently out for public review, with another for Schizophrenia not far behind it,” stated Rhonda Facile, Senior Director of Standards Development at CDISC. “We also expect standards for breast cancer, traumatic brain injury, dyslipidemia and COPD to be developed within the 2015 calendar year.” Completed CDISC TA standards that augment the CDISC foundational data standards include, but are not limited to, Alzheimer’s disease, Parkinson’s disease, polycystic kidney disease, asthma and diabetes.
CDISC is a 501(c)(3) global non-profit charitable organization, with over 350 supporting member organizations from across the clinical research and healthcare arenas. Through the efforts of volunteers around the globe, CDISC catalyzes productive collaboration to develop industry-wide data standards enabling the harmonization of clinical data and streamlining research processes from protocol through analysis and reporting, including the use of electronic health records to facilitate the collection of high quality research data. The CDISC standards and innovations can significantly decrease the time and cost of medical research and improve quality, thus contributing to the faster development of safe and effective medical products and a learning healthcare system. The CDISC Vision is to inform patient care and safety through higher quality medical research. For more information, please visit the CDISC website.